Formulation, toxicity, and antifungal activity in vitro of liposome-encapsulated nystatin as therapeutic agent for systemic candidiasis | Zendy

R T Mehta | Zendy; Roy L. Hopfer | Zendy; L A Gunner | Zendy; R. L. Juliano | Zendy; Gabriel López-Berestein | Zendy

Open Access

Formulation, toxicity, and antifungal activity in vitro of liposome-encapsulated nystatin as therapeutic agent for systemic candidiasis

Author(s) -

R T Mehta,

Roy L. Hopfer,

L A Gunner,

R. L. Juliano,

Gabriel López-Berestein

Publication year - 1987

Publication title -

antimicrobial agents and chemotherapy

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.07

H-Index - 259

eISSN - 1070-6283

pISSN - 0066-4804

DOI - 10.1128/aac.31.12.1897

Subject(s) - nystatin , liposome , candida albicans , toxicity , in vitro , pharmacology , antifungal , microbiology and biotechnology , biological activity , vesicle , drug , antifungal drug , chemistry , biology , biochemistry , membrane , organic chemistry

Multilamellar vesicles containing nystatin (NYS) were compared with vesicles containing the free drug for toxicity to erythrocytes and for antifungal activity in vitro. Liposomal nystatin was as active as free NYS was against a wide variety of yeasts and fungi. The antifungal activity against Candida albicans was maintained with different liposome compositions and without sterols. Liposome encapsulation also protected the erythrocytes from the toxicity of free NYS.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research